Our mission: eradicate cancer and the suffering it causes
Evercore ISI HealthCONx conference
Kevin Conroy, Chairman and CEO
November 30, 2021
EXACT SCIENCES
1
Safe harbor statement
Forward-Looking Statements
Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management's current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission. Specifically, the Company's most recent annual report on Form 10-K and any subsequently filed quarterly reports on Form 10-Q and current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company's projections of forward-looking statements.
EXACT SCIENCES
2
EXACT SCIENCES
Detecting cancer earlier at every step, starting with screening
Diagnosis
Recurrence
Relapse
Tumor burden
Hereditary cancer/
Prognosis/
Minimal
Recurrence
Therapy
Screening
Therapy selection
residual disease
monitoring
selection
EXACT SCIENCES
3
We plan to lead 3 of the largest impact opportunities in cancer diagnostics
$25B
$18B
$15B
multi-cancer early detection
colorectal cancer screening
minimal residual disease
and recurrence monitoring
2.0
colon cancer blood test
T
TARDIS
Notes: Cologuard 2.0 and colon cancer blood test have not been cleared or approved by the FDA; U.S. TAMs only
Source: Exact Sciences estimates, includes U.S. markets only
EXACT SCIENCES
4
Supporting new innovative tests with rigorous scientific evidence
expected data readouts
U.S. TAM
current evidence
1H 2022
2H 2022
1H 2023
Cologuard 2.0
$18B
colon blood
multi-cancer
$25B
minimal residual
$15B
disease
case-control
prospective
Note: these tests have not been cleared or approved by the FDA; Cologuard 2.0 and colon blood prospective data may not read out simultaneously
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
EXACT Sciences Corporation published this content on 30 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 November 2021 21:30:18 UTC.
Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Companyâs products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Companyâs flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patientâs breast tumor tissue.
EXACT SCIENCES CORPORATION 
